|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jänne PA, Wang X, Socinski MA, Crawford J,
Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero
MA, Kratzke R, et al: Randomized phase II trial of erlotinib alone
or with carboplatin and paclitaxel in patients who were never or
light former smokers with advanced lung adenocarcinoma: CALGB 30406
trial. J Clin Oncol. 30:2063–2069. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suda K, Rivard CJ, Mitsudomi T and Hirsch
FR: Overcoming resistance to EGFR tyrosine kinase inhibitors in
lung cancer, focusing on non-T790M mechanisms. Expert Rev
Anticancer Ther. 17:779–786. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Westover D, Zugazagoitia J, Cho BC, Lovly
CM and Paz-Ares L: Mechanisms of acquired resistance to first- and
second-generation EGFR tyrosine kinase inhibitors. Ann Oncol.
29(suppl_1): i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Britzen-Laurent N, Lipnik K, Ocker M,
Naschberger E, Schellerer VS, Croner RS, Vieth M, Waldner M,
Steinberg P, Hohenadl C, et al: GBP-1 acts as a tumor suppressor in
colorectal cancer cells. Carcinogenesis. 34:153–162. 2013.
View Article : Google Scholar
|
|
7
|
Yu CJ, Chang KP, Chang YJ, Hsu CW, Liang
Y, Yu JS, Chi LM, Chang YS and Wu CC: Identification of
guanylate-binding protein 1 as a potential oral cancer marker
involved in cell invasion using omics-based analysis. J Proteome
Res. 10:3778–3788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamakita I, Mimae T, Tsutani Y, Miyata Y,
Ito A and Okada M: Guanylate binding protein 1 (GBP-1) promotes
cell motility and invasiveness of lung adenocarcinoma. Biochem
Biophys Res Commun. 518:266–272. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tipton AR, Nyabuto GO, Trendel JA, Mazur
TM, Wilson JP, Wadi S, Justinger JS, Moore GL, Nguyen PT and Vestal
DJ: Guanylate-binding Protein-1 protects ovarian cancer cell lines
but not breast cancer cell lines from killing by paclitaxel.
Biochem Biophys Res Commun. 478:1617–1623. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ji X, Zhu H, Dai X, Xi Y, Sheng Y, Gao C,
Liu H, Xue Y, Liu J, Shi J, et al: Overexpression of GBP1 predicts
poor prognosis and promotes tumor growth in human glioblastoma
multiforme. Cancer Biomark. 25:275–290. 2019. View Article : Google Scholar
|
|
11
|
Quintero M, Adamoski D, Reis LMD, Ascenção
CFR, Oliveira KRS, Gonçalves KA, Dias MM, Carazzolle MF and Dias
SMG: Guanylate-binding protein-1 is a potential new therapeutic
target for triple-negative breast cancer. BMC Cancer. 17:7272017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu T, Zhao Y, Hu Z, Li J, Chu D, Zhang J,
Li Z, Chen B, Zhang X, Pan H, et al: MetaLnc9 facilitates lung
cancer metastasis via a PGK1-activated AKT/mTOR pathway. Cancer
Res. 77:5782–5794. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niederst MJ, Sequist LV, Poirier JT,
Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN,
Moran T, et al: RB loss in resistant EGFR mutant lung
adenocarcinomas that transform to small-cell lung cancer. Nat
Commun. 6:63772015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakata A, Yoshida R, Yamaguchi R, Yamauchi
M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M,
et al: Elevated β-catenin pathway as a novel target for patients
with resistance to EGF receptor targeting drugs. Sci Rep.
5:130762015. View Article : Google Scholar
|
|
16
|
Smyth GK: Limma: linear models for
microarray. Bioinformatics and Computational Biology Solutions
Using R and Bioconductor. Gentleman R, Carey VJ, Huber W, Irizarry
RA and Dudoit S: Springer; New York, NY: pp. 397–420. 2005,
View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Massagué J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang H, Geng YH, Wang P, Zhou YT, Yang H,
Huo YF, Zhang HQ, Li Y, He HY, Tian XX, et al: Extracellular ATP
promotes breast cancer invasion and epithelial-mesenchymal
transition via hypoxia-inducible factor 2α signaling. Cancer Sci.
110:2456–2470. 2019.PubMed/NCBI
|
|
21
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thomas H: Colorectal cancer: CRC
endothelial regulation. Nat Rev Gastro Hepat. 13:6822016.
View Article : Google Scholar
|
|
24
|
Wadi S, Tipton AR, Trendel JA, Khuder SA
and Vestal DJ: hGBP-1 expression predicts shorter progression-free
survival in ovarian cancers, while contributing to paclitaxel
resistance. J Cancer Ther. 7:994–1007. 2016. View Article : Google Scholar
|
|
25
|
Duan Z, Foster R, Brakora KA, Yusuf RZ and
Seiden MV: GBP1 overexpression is associated with a paclitaxel
resistance phenotype. Cancer Chemother Pharmacol. 57:25–33. 2006.
View Article : Google Scholar
|
|
26
|
Zhou JW, Tang JJ, Sun W and Wang H: PGK1
facilities cisplatin chemoresistance by triggering HSP90/ERK
pathway mediated DNA repair and methylation in endometrial
endometrioid adeno-carcinoma. Mol Med. 25:112019. View Article : Google Scholar
|
|
27
|
Schneider CC, Archid R, Fischer N, Bühler
S, Venturelli S, Berger A, Burkard M, Kirschniak A, Bachmann R,
Königsrainer A, et al: Metabolic alteration–Overcoming therapy
resistance in gastric cancer via PGK-1 inhibition in a combined
therapy with standard chemotherapeutics. Int J Surg. 22:92–98.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun S, Liang X, Zhang X, Liu T, Shi Q,
Song Y, Jiang Y, Wu H, Jiang Y, Lu X, et al: Phosphoglycerate
kinase-1 is a predictor of poor survival and a novel prognostic
biomarker of chemoresistance to paclitaxel treatment in breast
cancer. Br J Cancer. 112:1332–1339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fu D, He C, Wei J, Zhang Z, Luo Y, Tan H
and Ren C: PGK1 is a potential survival biomarker and invasion
promoter by regulating the HIF-1alpha-mediated
epithelial-mesenchymal transition process in breast cancer. Cell
Physiol Biochem. 51:2434–2444. 2018. View Article : Google Scholar
|
|
30
|
Byers LA, Diao L, Wang J, Saintigny P,
Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al: An
epithelial-mesenchymal transition gene signature predicts
resistance to EGFR and PI3K inhibitors and identifies Axl as a
therapeutic target for overcoming EGFR inhibitor resistance. Clin
Cancer Res. 19:279–290. 2013. View Article : Google Scholar
|
|
31
|
Lou W, Chen Y, Zhu KY, Deng H, Wu T and
Wang J: Polyphyllin I overcomes EMT-associated resistance to
erlotinib in lung cancer cells IL-6/STAT3 pathway inhibition. Biol
Pharm Bull. 40:1306–1313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jakobsen KR, Demuth C, Sorensen BS and
Nielsen AL: The role of epithelial to mesenchymal transition in
resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Transl Lung Cancer Res.
5:172–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weng CH, Chen LY, Lin YC, Shih JY, Lin YC,
Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al:
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per
se is a common mechanism for acquired resistance to EGFR TKI.
Oncogene. 38:455–468. 2019. View Article : Google Scholar
|
